There have been some eventful days recently in terms of important pharmaceutical regulations and legislation:
- Community pharma strategy to which we dedicated a post on LinkedIn
- Proposal for a Data Governance Regulation. Re-use of certain public sector data, including health data, which is key to boosting biomedical research.
- RD on observational studies. Simplifying administrative procedures, more efficient assessment of the quality and suitability of each study and updating guarantees on transparency and access to information from these studies.
- Reference price order
- COVID-19 vaccination strategy in Spain.
- Public consultation on the Science, Technology and Innovation Bill. The consultation period is now open.
This post is also available in: Spanish
